Myocet is in its last clinical trial phase prior to FDA review. The trial is enrolling patients to evaluate the investigative chemotherapy agent Myocet (liposomal encapsulated doxorubicin) in addition to standard therapy for HER2-positive breast cancer.
Myocet is a chemotherapy agent that contains the active form of doxorubicin, you might better know it as Adriamycin. This chemotherapy drug is formulated to reduce the side effects associated with Adriamycin. Myocet allows for more of the active drug to be delivered directly to cancer cells, sparing healthy cells from being damaged.
This trial will directly compare the standard option of Herceptin and Taxol to the combination of Myocet, Herceptin and Taxol. Researchers are now enrolling patients with metastatic, HER2-positive breast cancer with a goal in mind to determine if the addition of Myocet to standard therapy can increase response to therapy or regression of cancer.
